In the Tsc2+/- study reported here, we observed that the combination treatment cohort had a lower cystadenoma score than the single-agent CCI-779 cohort in both the 6–8 month and 10–12 month groups, although this difference was not statistically significant (Figure 1a–d). Here, TSC2 is linked to cystadenoma.